Loading stock data…
ERNA
$7.21-0.32 (-4.25%)
Market ClosedLast close May 11
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ernexa Therapeutics Inc. in the Healthcare sector is trading at $7.21. The stock is currently near its 52-week low of $3.18, remaining 71.1% below its 200-day moving average. Technical signals show neutral RSI of 70 and bullish MACD crossover, explaining why ERNA maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 70) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$7.21
Potential Upside
5%
Whystock Fair Value$7.57
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus1 analysts
Mean target$30.00+316.1%
Range$30.00 – $30.00
Fundamentals
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflamma...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.57M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
6.85
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-586.59%
Volume
Today's trading volume
479,500
Recent News
Ernexa Therapeutics (ERNA) Preclinical Data Shows 100% Survival and Complete Tumor Clearance in Ovarian Cancer Models
Ernexa Therapeutics reported new preclinical findings showing its ERNA-101 cell therapy candidate achieved complete tumor elimination and long-term survival in ovarian cancer models when combined with PD-1 blockade. Key Investor TakeawaysErnexa Therapeutics (NASDAQ:ERNA) released preclinical ovarian cancer data showing ERNA-101 achieved complete tumor clearance and 100% survival in treated mice.
BC-Most Active Stocks
YY Group Holdings Ltd. 56,330,377 0.4678
Ernexa Therapeutics First Half 2025 Earnings: US$2.91 loss per share (vs US$33.78 loss in 1H 2024)
NasdaqCM:ERNA 1 Year Share Price vs Fair Value Explore Ernexa Therapeutics's Fair Values from the Community and select...
Ernexa Therapeutics announces 1-for-15 reverse stock split
Ernexa Therapeutics (ERNA) announced a reverse stock split of its issued and outstanding shares of common stock, par value $0.005 per share at a ratio of 1-for-15, effective June 12, 2025 at 12:01 a.m. Eastern Time. The Company’s Common Stock is expected to begin trading on a split-adjusted basis when the market opens on June 12, 2025, under the existing trading symbol “ERNA.” The Company is effecting the reverse split to regain compliance with the $1.00 minimum bid price required for continued